CASR and autoimmune polyendocrine syndrome type 1: CaSR autoantibodies and CaSR-activating autoantibodies have previously been identified in patients with idiopathic hypoparathyroidism and autoimmune polyendocrine syndrome type 1 (APS1) [8] and have also been described in a patient treated with nivolumab [7].